Upstream Bio's (UPB) Sell (D-) Rating Reaffirmed at Weiss Ratings

Key Points

• Upstream Bio's stock is reaffirmed with a "sell (D-)" rating by Weiss Ratings, indicating unfavorable investment sentiment.
• The company reported a loss of $0.74 EPS for the last quarter, falling short of analysts' expectations and reflecting significant financial challenges.
• Institutional investors are adjusting their positions, with Bain Capital increasing its stake by 6.3% and Norges Bank acquiring a new stake worth $10.65 million.

Upstream Bio (NASDAQ:UPB - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Upstream Bio Stock Performance

Upstream Bio stock traded up $0.25 during midday trading on Wednesday, hitting $18.92. 328,407 shares of the stock were exchanged, compared to its average volume of 453,305. Upstream Bio has a 1 year low of $5.14 and a 1 year high of $29.46. The company has a 50 day moving average price of $17.50 and a two-hundred day moving average price of $12.35.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $0.32 million. Upstream Bio had a negative return on equity of 35.90% and a negative net margin of 3,836.58%. On average, research analysts forecast that Upstream Bio will post -4.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Upstream Bio

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bain Capital Life Sciences Investors LLC raised its position in shares of Upstream Bio by 6.3% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 2,439,538 shares of the company's stock valued at $26,786,000 after acquiring an additional 144,216 shares in the last quarter. Norges Bank acquired a new stake in Upstream Bio in the second quarter worth $10,650,000. Geode Capital Management LLC increased its position in Upstream Bio by 57.5% in the second quarter. Geode Capital Management LLC now owns 646,635 shares of the company's stock worth $7,101,000 after buying an additional 235,958 shares during the period. Woodline Partners LP increased its position in Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company's stock worth $3,409,000 after buying an additional 30,552 shares during the period. Finally, Parkman Healthcare Partners LLC acquired a new stake in Upstream Bio in the first quarter worth $1,429,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.